A5020468514- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Adrenal Hormones and Disorders
- Adrenal and Paraganglionic Tumors
- Glioma Diagnosis and Treatment
- Hormonal Regulation and Hypertension
- Neuroendocrine Tumor Research Advances
- Hormonal and reproductive studies
- Meningioma and schwannoma management
- Helicobacter pylori-related gastroenterology studies
- Myasthenia Gravis and Thymoma
- Thyroid Disorders and Treatments
- Lipid metabolism and disorders
- Childhood Cancer Survivors' Quality of Life
- Genetics and Neurodevelopmental Disorders
- Diet and metabolism studies
- Diabetes and associated disorders
- Eosinophilic Esophagitis
- Neuroblastoma Research and Treatments
- Galectins and Cancer Biology
- Ophthalmology and Eye Disorders
- Sexual Differentiation and Disorders
- Kidney Stones and Urolithiasis Treatments
- Gastroesophageal reflux and treatments
- Neurofibromatosis and Schwannoma Cases
Skåne University Hospital
2015-2025
Lund University
2011-2025
Malmö University
2005-2022
Diabetes Australia
2015
Pfizer (United States)
2005-2006
Uppsala University Hospital
1995-2005
University of Copenhagen
1991-1997
Rigshospitalet
1997
Linköping University Hospital
1991-1997
Medical University of South Carolina
1992
Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet more physiological exposure-time cortisol profile. The aim compare pharmacokinetics metabolic between OD the same daily dose of thrice-daily (TID) conventional tablets. We conducted an open, randomized, two-period, 12-wk crossover multicenter trial 24-wk extension at five university hospital...
To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects temozolomide (TMZ) treatment.Electronic survey to ESE members Dec 2015-Nov 2016.Reports on 166 (40 PC, 125 APT, 1 unclassified) were obtained. Median age at diagnosis was 43 (range 4-79) years. 69% the clinically functioning, most frequent immunohistochemical subtype corticotroph (45%). Ki-67 index did not distinguish APT from median 7% 10%...
Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety efficacy children adults subject to considerable scrutiny. In 2001, a statement from the Research Society (GRS) concluded 'for approved indications, is safe'; however, highlighted number of areas on-going surveillance long-term safety, including cancer risk, impact on glucose homeostasis, high dose pharmacological rhGH treatment. Over intervening there have publications addressing with regard mortality,...
Thirty-six patients with adult-onset GH deficiency (GHD) were examined before and after 9 months of treatment recombinant GH. The study was conducted as a double blind, placebo-controlled, 21-month trial cross-over design, each period lasting for months. same dose, adjusted body surface area, given to men (n = 21) women 15), the effects on composition biochemical parameters evaluated respect gender. extent GHD, assessed therapy from basal secretion release in response provocative tests, did...
We examined the effect of GH supplementation on psychological capacity and sense well-being in 36 patients with adult-onset deficiency (GHD). Recombinant human was given a 21-month cross-over, double blind trial, quality life assessed by using three self-rating questionnaires: Hopkins Symptom Check List (HSCL), Nottingham Health Profile (NHP), Psychological General Well-Being index. In addition, at final examination spouses completed short questionnaire concerning their partner. Before...
Among 49 patients with carcinoid tumors given long term therapy (mean, 8 months; range, 3-36) human leukocyte-derived interferon-a (huLe-IFNa), hypothyroidism occurred in 5 andthyrotoxicosis 2. Antibodies against thyroid microsomal antigen and/or thyroglobulin were found 13 patients. In 7 of these, 3 whom developed hypothyroidism, the antibodies appeared aferthe start therapy. During treatment, an increase proportions circulating activated surface HLA-DR-positive T-helper and T-suppressor...
In autoimmune gastritis antibodies against a membrane-bound parietal cell antigen of previously unknown function are present in the sera patients. this study, vesicular membrane preparation porcine gastric mucosa cells was found to be potent antigenic source. This blocked greater than 90% antibody binding lysate cells. The fraction contained H+,K+-ATPase (EC 3.6.1.36) as major protein, which sodium dodecyl sulfate-polyacrylamide gel electrophoresis migrated with weight 92 kD. After reduction...
Context: In clinical practice, patients with acromegaly may be switched from therapy long-acting somatostatin analogs to pegvisomant. The effect of changing therapies on glucose homeostasis and safety has not been reported. Objectives: objectives this study were monitor changes in IGF-I levels, glycemic control, safety, particularly liver function tumor size. Design: This was a multicenter, open-label, 32-wk trial study. Setting: performed at outpatient clinics. Patients: Fifty-three...
Patients with hypopituitarism have an increased standardized mortality rate. The basis for this has not been fully clarified.To investigate in detail the cause of death a large cohort patients subjected to long-term follow-up.All-cause and cause-specific 1286 Swedish prospectively monitored KIMS (Pfizer International Metabolic Database) 1995-2009 were compared general population data National Cause Death Registry. In addition, events reported KIMS, medical records, postmortem reports...
Experimental studies in vitro indicate that insulin‐like growth factor 1 (IGF‐1) could be of importance for normal bone and remodelling, but the clinical relevance these observations is unknown. In 12 consecutive young to middle‐aged male patients (mean age (±SD) 46 ± 8 years, range 30–57 years) with symptomatic idiopathic osteoporosis, plasma concentrations IGF‐1 were significantly lower than healthy subjects (0.51 0.25 vs. 0.73 0.23 U ml −1 ; P < 0.01). The mineral densities spine,...
Locally aggressive pituitary tumors (LAPT) and carcinomas respond poorly to conventional therapy cytotoxic drugs. Temozolomide (TMZ) is an oral alkylating drug with good tolerability, approved for treatment of malignant gliomas. The experience its use in limited. We report on 24 patients (16 LAPTs, 8 carcinomas) treated TMZ a median 6 months (range 1–23). Follow-up ranged from 4 91 32.5 months. 19/24 were hormone secreting (PRL 9, ACTH 4, GH GH/PRL 2). Ki-67 was 2–50% 5–80% carcinomas....
Objective : We aimed to investigate the efficacy of pegvisomant in patients with acromegaly resistant long-term (≧ 24-month), high-dose treatment octreotide-LAR (40 mg/month) or lanreotide (120 mg/month). Design This was an open, prospective study. Subjects and Methods studied 16 (nine women; aged 28–61 years). The main outcome measures were IGF-I levels, blood pressure, glucose tolerance safety (liver function tumor size). Pegvisomant given at doses 10–40 mg s.c. daily. Dose titration...
TSH-secreting pituitary adenomas (TSHomas) are rare. Epidemiological data scant and there no reports on national incidence. The objective of the study was to estimate Swedish incidence prevalence TSHomas. This an observational study. conducted at tertiary referral centers. Pituitary Registry World Health Organization International Statistical Classification Diseases Related Problems coding all university hospitals were used identify patients diagnosed with TSHomas 1990–2010. identified...
Whether patients with Cushing disease (CD) in remission have increased mortality is still debatable. To study overall and disease-specific predictive factors an unselected nationwide cohort of CD. A retrospective diagnosed CD, identified the Swedish National Patient Registry between 1987 2013. Medical records were systematically reviewed to verify diagnosis. Standardized ratios (SMRs) 95% CIs calculated Cox regression models used identify predictors mortality. Of 502 CD (n = 387 women; 77%),...
To describe clinical and pathological characteristics treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC).Electronic survey August 2020-May 2021.96% 171 (121 APT, 50 PC), initially presented as macro/giant tumours, 6 were microadenomas (5 corticotroph). Ninety-seven considered clinically benign, demonstrated behaviour after 5.5 years (IQR: 2.8-12). Of the patients, 63% men. Adrenocorticotrophic hormone (ACTH)-secreting constituted 30% APT/PC,...
Abstract Aggressive pituitary tumors (APTs) and carcinomas (PCs) are heterogeneous with regard to clinical presentation, proliferative markers, course, response therapy. Half of them show an aggressive course only many years after the first apparently benign presentation. APTs PCs share several properties, but a Ki67 index greater than or equal 10% extensive p53 expression more prevalent in PCs. Mutations TP53 ATRX most common genetic alterations; their detection might be value for early...
Thirty-eight women, aged 25–65 yr, with androgen deficiency due to hypopituitarism were treated oral dehydroepiandrosterone (DHEA; 30 mg/d if <45 yr of age and 20 mg ≥45 age) for 6 months in a randomized, placebo-controlled, double blind study, followed by 6-month open treatment period. The administration DHEA raised the serum levels DHEAS normal age-related reference ranges increased androstenedione T subnormal levels. Androgen effects on skin and/or pubic axillary hair observed 84% (32 38)...
Abstract Ghrelin is a recently discovered gastric peptide that increases appetite, glucose oxidation, and lipogenesis stimulates the secretion of GH. In contrast to ghrelin, GH promotes lipolysis, production, insulin secretion. Both ghrelin are suppressed by intake nutrients, especially glucose. The role in regulation has not yet been established. We investigated effect on circulating levels relation its effects glucose, insulin, body composition, adipocyte-derived peptides leptin...
OBJECTIVE Binding sites specific for growth hormone have been identified in the brain, but action of GH on central nervous system is still poorly understood. DESIGN In a double‐blind, placebo‐controlled 21‐month trial with cross‐over design, each treatment period lasting 9 months, we investigated long‐term effect cerebrospinal fluid (CSF) concentrations some brain neurotransmitters and thyroid hormones importance mood cognition. PATIENTS Twenty‐four patients documented deficiency acquired...